GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aditxt
Aditxt is a biotech company focused on monitoring and modulating the immune system. Its stock price reflects speculative interest in this complex yet promising area of medicine.
Share prices of companies in the market segment - Pharma immune
Aditxt is a biotech company focused on monitoring and modulating the immune system to treat autoimmune diseases and transplant rejection. We've categorized it under "Pharma: Immunology." The chart below shows the dynamics of the personalized immunology sector.
Broad Market Index - GURU.Markets
Aditxt is a biotech company focused on monitoring and modulating the immune system. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ADTX - Daily change in the company's share price Aditxt
For Aditxt, Inc., an immunology company, daily volatility reflects sensitivity to news about the development of its diagnostic and therapeutic platforms. This metric is an indicator of progress in personalized medicine.
Daily change in the price of a set of shares in a market segment - Pharma immune
Aditxt develops technologies for monitoring and modulating the immune system. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this field, allowing you to assess ADTX stock performance in the context of the overall industry.
Daily change in the price of a broad market stock, index - GURU.Markets
Aditxt is a biotech company working in the field of immunology. Its shares, like many in the sector, are extremely volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aditxt
Aditxt, Inc.'s year-to-date performance tells the story of its ambitious platform for monitoring and modulating the immune system. Its trailing-12-month market cap reflects investors' faith in its ability to commercialize its AditxtScore assays and develop therapeutics, a long-term but high-risk goal.
Annual dynamics of market capitalization of the market segment - Pharma immune
Aditxt, as a biotech company with a diversified portfolio, is a complex asset. Its performance will reflect the success of its various programs, from immune monitoring to therapeutics. Compared to the sector, its model diversifies risks but may underperform compared to companies with single-player blockbusters.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aditxt, a biotech company working on monitoring and modulating the immune system, is striving to personalize medicine. Its year-over-year market capitalization reflects investors' confidence in its ability to create a platform that can predict and modify the human immune response.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aditxt
Aditxt is a biotech company focused on immune system monitoring. Its monthly performance reflects progress in the commercialization of its tests and the development of therapeutics. News about partnerships and regulatory approvals are key.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Immunology is one of the most complex and promising areas in medicine. The dynamics of this biotech sector, visible on the chart, reflect investors' belief in the possibility of "manipulating" the immune system. Companies like Aditxt are conducting their scientific research in this cutting-edge field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aditxt, a company working in the field of immune system monitoring, is betting on personalized medicine. The company's shares are volatile and driven by news of its test rollouts rather than by overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aditxt
Aditxt, a company developing technologies for monitoring and modulating the immune system, operates in a complex scientific field. Its weekly stock price is driven by news about the validation of its tests and progress in its therapeutic programs, creating high uncertainty and volatility.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Aditxt develops technologies for monitoring and modulating the immune system. It offers a personalized approach to medicine. The company's shares are sensitive to news about the validation and implementation of its tests. The chart will help isolate the impact of these events from the overall dynamics of the healthcare sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aditxt develops technologies for monitoring the immune system. Its shares are sensitive to news about the validation and implementation of its tests. The chart will help isolate the impact of these events from the overall stock market dynamics.
Market capitalization of the company, segment and market as a whole
ADTX - Market capitalization of the company Aditxt
Aditxt's market capitalization reflects investors' valuation of its developments in immune system monitoring and modulation. The chart illustrates its ambitious goals of developing personalized therapeutic approaches. Its low price and high volatility reflect the very early stage of its technology and market skepticism.
ADTX - Share of the company's market capitalization Aditxt within the market segment - Pharma immune
Aditxt is a biotech company focused on monitoring and modulating the immune system. Its market share is small, but it is focused on personalized medicine. Its market cap reflects the potential of its AditxtScore diagnostic tests and its therapeutic programs for autoimmune diseases.
Market capitalization of the market segment - Pharma immune
This chart shows the total value of the entire biotech sector specializing in immune therapy. For Aditxt, a company working in this field, this line is a map of the future of medicine. The chart's rise reflects investors' belief that modulating the immune system is the key to treating the most complex diseases, from cancer to autoimmune disorders.
Market capitalization of all companies included in a broad market index - GURU.Markets
Aditxt is a company developing technologies for monitoring and modulating the immune system. Its market capitalization is based on the value of personalized immunology. This represents the market share of the dream of "tuning" one's immune system for health and longevity.
Book value capitalization of the company, segment and market as a whole
ADTX - Book value capitalization of the company Aditxt
Aditxt is a biotechnology company specializing in monitoring and modulating the immune system. Its book value is its scientific and financial capital. It consists of cash used for R&D and commercialization of its technologies. How has this capital changed? The chart below shows.
ADTX - Share of the company's book capitalization Aditxt within the market segment - Pharma immune
Aditxt is a biotech company focused on monitoring and reprogramming the immune system. Its operations require a laboratory to develop its diagnostic and therapeutic platforms. The chart shows the company's share of immunology R&D infrastructure.
Market segment balance sheet capitalization - Pharma immune
Aditxt is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Aditxt focuses on monitoring and modulating the immune system, and its capital is intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Aditxt's assets are not drugs, but laboratories and a technology platform for monitoring and modulating the immune system. Its book value reflects its scientific foundation for developing personalized therapeutic approaches in immunology. The chart demonstrates the scale of this company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aditxt
Aditxt is a biotech company focused on monitoring and modulating the immune system. Its market value is determined by its technologies and their potential in personalized medicine and transplantation.
Market to book capitalization ratio in a market segment - Pharma immune
Aditxt is a biotech company working in the field of immune system monitoring. The chart shows how investors view its technology and its potential for use in transplantation, autoimmune diseases, and other areas of medicine.
Market to book capitalization ratio for the market as a whole
Aditxt develops technologies for monitoring and modulating the immune system. Its market valuation is based on the promise of personalized medicine. This chart demonstrates the premium investors are willing to pay for cutting-edge healthcare technologies that promise more precise and personalized treatments.
Debts of the company, segment and market as a whole
ADTX - Company debts Aditxt
Aditxt, a biotech company working in immune system monitoring, is raising capital for the commercialization of its tests and for R&D. This chart shows the company's financial needs during the commercialization phase of its new and complex diagnostic technology.
Market segment debts - Pharma immune
Aditxt is a biotech company developing technologies to monitor and modulate the immune system. This chart illustrates how a company at the forefront of immunology funds its diverse and ambitious R&D programs, a capital-intensive and risky endeavor.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aditxt
Aditxt develops technologies for monitoring and modulating the immune system. Commercializing such complex diagnostic and therapeutic platforms is a lengthy and capital-intensive process. This chart illustrates the company's reliance on debt to finance its cutting-edge, yet unprofitable, research.
Market segment debt to market segment book capitalization - Pharma immune
Aditxt is a biotech company working in the field of immune system monitoring and modulation. This is a complex and promising field. This chart shows how the company is funding its ambitious research. It relates its debt structure to the overall financial picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Aditxt develops technologies for monitoring and modulating the immune system. This is a cutting-edge area of personalized medicine, requiring significant R&D investment. How heavily is the company reliant on debt? This graph of total debt in the economy helps assess the riskiness of its financial model in the biotech sector.
P/E of the company, segment and market as a whole
P/E - Aditxt
Aditxt is a biotech company focused on monitoring and modulating the immune system. This chart shows how investors view its ambitious but complex scientific program. The valuation is volatile and depends on news about the development of its diagnostic and therapeutic platforms.
P/E of the market segment - Pharma immune
Aditxt, Inc. is a biotech company focused on monitoring and modulating the immune system. This chart illustrates the average valuation in the immunopharmaceutical sector, where investors evaluate the potential of technologies to personalize treatments for immune diseases.
P/E of the market as a whole
Aditxt, Inc. is a biotech company developing technologies for monitoring and modulating the immune system. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether ADITX's valuation reflects faith in the future of personalized immunology or follows broader trends in the healthcare sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aditxt
Aditxt is a biotech company focused on monitoring and modulating the immune system. Its goal is to personalize treatment approaches for allergies, autoimmune diseases, and organ rejection. This chart shows how much investors believe in the future of immune monitoring and the commercial potential of the company's technologies.
%20P%2FE%20Aditxt&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aditxt&v=1772537052267 "Chart of the company's future (projected) P/E Aditxt")
Future (projected) P/E of the market segment - Pharma immune
Aditxt is a biotech company developing technologies for monitoring and modulating the immune system. Its goal is to make immunity more personalized. The chart reflects future profit forecasts for the sector, helping to understand the level of investor confidence in this ambitious scientific approach and its future applications.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772537052313 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Aditxt is a biotech company focused on monitoring and modulating the immune system. It offers a personalized approach to health. This market sentiment chart helps us understand how willing investors are to invest in complex and science-intensive platforms that could form the basis for future preventative medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772537052376 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aditxt
Aditxt is a biotechnology company focused on monitoring and modulating the immune system. It develops technologies for personalized diagnostics and therapeutics. Financial indicators reflect research expenditures. This chart shows investments in the cutting-edge field of immunology, which is key to treating many diseases.
Profit of companies in the market segment - Pharma immune
Aditxt, Inc. is a biotechnology company focused on monitoring and modulating the immune system. It develops technologies for accurately assessing the state of human immunity. This chart shows the overall profitability of the immunopharmaceutical sector, where a personalized approach to immune health is one of the most promising areas.
Overall market profit
Aditxt is a biotech company specializing in monitoring and modulating the immune system. The need for such technologies is growing as personalized medicine advances. The company's growth depends on scientific breakthroughs, not short-term economic cycles, as can be seen in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aditxt
Aditxt is a biotech company focused on monitoring and modulating the immune system. Future revenue depends on the commercialization of its diagnostic tests and the success of its therapeutic programs. This chart reflects analyst expectations regarding the prospects of personalized immunology.
%20profit%20of%20the%20company%20Aditxt&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aditxt&v=1772537052490 "Graph of future (projected) profit of the company Aditxt")
Future (predicted) profit of companies in the market segment - Pharma immune
Aditxt develops technologies for monitoring and modulating the immune system. The company's goal is to create personalized therapeutic solutions for immune diseases. This chart shows revenue expectations for the immunopharmaceuticals sector, providing context for evaluating Aditxt's ambitious platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772537052517 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Aditxt is a biotech company working in the field of immune system monitoring and modulation. Its development depends on the commercialization of its tests and therapeutic approaches. This economic outlook affects the investment climate in the biotech sector and spending on innovative diagnostics.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772537052542 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aditxt
Aditxt develops technologies for monitoring and modulating the immune system. Revenue is a key metric during the commercialization stage. This chart shows how investors view its platform and potential in personalized medicine and immunology.
P/S market segment - Pharma immune
Aditxt is a biotech company focused on monitoring and modulating the immune system. Their technologies aim to accurately determine the state of human immunity and develop therapies to restore balance in autoimmune diseases. This chart reflects the average revenue estimate for the sector, helping to assess the potential of this innovative approach.
P/S of the market as a whole
Aditxt is a biotech company focused on monitoring and modulating the immune system. This chart, which displays average revenue estimates, shows that the valuation of such early-stage companies is based on the potential of their technologies to become a key part of personalized medicine, rather than on current financial performance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aditxt
Aditxt is a biotech company focused on monitoring and modulating the immune system. It develops technologies for both immune diagnostics and therapies for autoimmune diseases. Its revenue valuation is important to the company, reflecting investor expectations for the commercialization of its diagnostic platform and the success of its therapeutic programs.
%20P%2FS%20Aditxt&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aditxt&v=1772537052637 "The graph of the company's future (projected) P/S Aditxt")
Future (projected) P/S of the market segment - Pharma immune
Aditxt is a biotech company focused on monitoring and modulating the immune system. This chart compares the company's estimated future sales with expectations for the life sciences sector. It shows how investors view its personalized medicine technologies, including immune diagnostics and immunotherapy development.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772537052675 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Aditxt is a biotech company specializing in monitoring and modulating the immune system. Its technologies can be used to personalize treatments for autoimmune diseases and transplant rejection. This chart of overall market expectations reflects investor belief that manipulating the immune system is the future of personalized medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772537052697 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aditxt
This figure reflects the revenue of Aditxt, a biotech company focused on monitoring and modulating the immune system. Revenue may be generated from the sale of diagnostic tests and services. The trend shows how successfully the company is commercializing its technologies for personalized medicine.
Sales of companies in the market segment - Pharma immune
Aditxt is a biotech company focused on monitoring and modulating the immune system. Its revenue structure, as it develops, will reflect revenue from its diagnostic tests and potentially from therapeutics, reflecting its comprehensive approach to immunology.
Overall market sales
Aditxt is a biotechnology company focused on monitoring and modulating the immune system. The company operates in the cutting-edge field of personalized medicine. This overall economic activity graph does not reflect Aditxt's prospects, which are determined by scientific breakthroughs and the ability to translate them into commercial products.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aditxt
Aditxt is a biotech company focused on monitoring and modulating the immune system. It develops technologies for personalized immunotherapy and diagnostics. Future revenue depends on the commercialization of its platform. This chart reflects analyst expectations for growth in the immune monitoring and personalized medicine market.
%20sales%20of%20the%20company%20Aditxt&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aditxt&v=1772537053016 "Schedule of future (projected) sales of the company Aditxt")
Future (projected) sales of companies in the market segment - Pharma immune
Aditxt develops technologies for monitoring and modulating the immune system. This chart illustrates the forecast for the medical testing market. Is the demand for personalized immune assessment tools growing, potentially revolutionizing medicine? This determines the overall outlook for the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772537053029 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Aditxt is a biotech company specializing in monitoring and modulating the immune system. Demand for its technologies depends on the advancement of personalized medicine. This overall economic activity impacts healthcare and R&D budgets, but for Aditxt, proving the clinical value of its approach to immune management is more important.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772537053200 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aditxt
Aditxt is a biotech company focused on monitoring and modulating the immune system. This chart shows its financial trajectory as it attempts to commercialize its technologies. Profitability depends on the successful launch of its diagnostic tests and the long-term development of its therapeutic programs, which requires significant investment.
Market segment marginality - Pharma immune
Aditxt, Inc. is a biotechnology company focused on monitoring and modulating the immune system. This chart reflects its financial performance at the development stage, where profitability is a future goal dependent on the commercialization of its diagnostic and therapeutic platforms.
Market marginality as a whole
Aditxt, Inc. is a biotechnology company focused on monitoring and modulating the immune system. Its technologies have potential applications in various fields of medicine. This gross margin chart reflects the overall health care sector and investor appetite for platform technologies with broad potential.
Employees in the company, segment and market as a whole
Number of employees in the company Aditxt
Aditxt is a biotech company working on monitoring and modulating the immune system. Its team of scientists and technicians is the backbone of its operations. This chart shows how the company is investing in personnel to develop its diagnostic tests and therapeutic programs, aiming to carve out a niche in personalized immunology.
Share of the company's employees Aditxt within the market segment - Pharma immune
Aditxt is a biotech company focused on monitoring and modulating the immune system. Developing such complex diagnostic and therapeutic platforms requires a team of immunologists, biologists, and data analysts. This graph shows the company's market share, reflecting the scale of its scientific work and technological ambitions.
Number of employees in the market segment - Pharma immune
Aditxt is a biotech company focused on monitoring and modulating the immune system. The chart illustrates employment in the immunopharmaceutical sector. The company's platforms enable immune system assessment and the development of therapies to restore balance in autoimmune diseases or after transplantation.
Number of employees in the market as a whole
Aditxt is a biotech company specializing in monitoring and modulating the immune system. Its technologies can be used for diagnostics and therapeutics. The company's growth depends on the implementation of its innovations. This chart shows overall employment, and Aditxt exemplifies how a deep understanding of biology creates new approaches in medicine and new jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aditxt (ADTX)
Aditxt is an immunology company developing both diagnostics (AditxtScore for immune monitoring) and therapeutics. This chart shows how the market values their comprehensive approach. It reflects the market value per employee, which is the combined value of their diagnostic and therapeutic R&D.
%20of%20the%20company%20Aditxt%20(ADTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aditxt-ADTX&v=1772537053859 "Chart of market capitalization per employee (in thousands of dollars) of the company Aditxt (ADTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Aditxt (ADTX) develops technologies for monitoring and modulating the immune system. In this cutting-edge field of medicine, this metric is a testament to their scientific platform. Their high capitalization per employee suggests that their tests and therapies are capable of giving people precise control over their immune status, which is key to personalized medicine.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772537053890 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Aditxt develops technologies for monitoring and modulating the immune system. Its valuation is based on the future potential of its diagnostic and therapeutic platforms. The chart shows a high valuation per employee, as personalized immune management is one of the most promising areas in medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772537053961 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aditxt (ADTX)
Aditxt is a biotech company developing technologies for monitoring and reprogramming the immune system. It's an early-stage R&D company. This graph shows the net loss per employee, reflecting the fact that every scientist at the company is an investment in the creation and validation of this complex immunological platform.
%20Chart%20Aditxt%20(ADTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aditxt-ADTX&v=1772537053989 "Company Profit Per Employee (in thousands of dollars) Chart Aditxt (ADTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Aditxt, Inc. is a biotech company focused on monitoring and modulating the immune system. In this cutting-edge field of medicine, efficiency per employee reflects the value of their diagnostic and therapeutic platforms. The graph shows the financial return generated by the team working on the personalized medicine of the future.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772537054084 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Aditxt is a company working in the field of immune system monitoring. They develop tests (AditxtScore) that are supposed to indicate immune status. They focus on R&D and diagnostics. This graph, showing average market performance, helps to understand the contrast with R&D businesses, where capital is invested in research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772537054165 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aditxt (ADTX)
Aditxt develops technologies for monitoring and modulating the immune system. During the commercialization phase, this graph will show market demand for their immunological tests and therapies. Increasing revenue per employee will indicate the successful implementation of their innovative solutions into clinical practice.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aditxt-ADTX&v=1772537054169 "Sales chart per company employee Aditxt (ADTX)")
Sales per employee in the market segment - Pharma immune
Aditxt (ADTX) is a biotech focused on monitoring and modulating the immune system. They develop both diagnostic tests and therapeutics. This chart shows the average output in the sector. For ADTX, this is an indicator of how productive their R&D team is in commercializing these complex immunological technologies.
Sales per employee for the market as a whole
Aditxt is a company working in the field of immune system monitoring and modulation. They provide diagnostic services (AditxtScore) and conduct R&D. This is a hybrid of R&D and services. This indicator demonstrates how effective their research-intensive model is in commercializing their tests and developments.
Short shares by company, segment and market as a whole
Shares shorted by company Aditxt (ADTX)
Aditxt (ADTX) is a biotech company with a wide range of interests, from immune system monitoring to therapeutics. This chart tracks short positions. Short positions may be driven by such a blurred focus and doubts about the company's ability to successfully complete any of its many projects.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aditxt-ADTX&v=1772537054247 "Short Shares Chart for the Company Aditxt (ADTX)")
Shares shorted by market segment - Pharma immune
Aditxt (ADTX) is a biotech company developing technologies for monitoring and modulating the immune system. This chart shows the total short position in the immunopharmaceuticals sector. It reflects investor concerns about the high level of competition in this space and the risks of clinical trials of new platforms.
Shares shorted by the overall market
Aditxt is a biotech holding company exploring immune monitoring and R&D. This chart illustrates the overall market pessimism. Investors see a hodgepodge of R&D projects and services. During times of fear, the market dislikes uncertainty and sells off such "unclear" holdings.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aditxt (ADTX)
Aditxt is a company working in the complex field of monitoring and "retraining" the immune system. This is fundamental science. This graph measures the "temperature" of faith in their technology. It "warms up" with news of research breakthroughs and "cools down" during the long months of waiting for a commercial product.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aditxt-ADTX&v=1772537054446 "RSI 14 indicator chart for the company's stock Aditxt (ADTX)")
RSI 14 Market Segment - Pharma immune
Aditxt (ADTX) is a biotech company working on "monitoring" and "retraining" the immune system to treat autoimmune diseases and allergies. This chart tracks overall sentiment in the Pharma/Immunology sector. It helps investors understand whether ADTX's performance reflects its trials or whether the overall sector is overheated or oversold.
RSI 14 for the overall market
For Aditxt (ADTX), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ADTX (Aditxt)
Aditxt is an immunology company developing both diagnostic tests (AditxtScore) for immune monitoring and therapeutics (Adimune). This chart shows the speculative average 12-month price target from analysts, reflecting their view on this dual business model.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ADTX-Aditxt&v=1772537054616 "A chart showing analyst consensus forecasts for the expected stock price. ADTX (Aditxt)")
The difference between the consensus estimate and the actual stock price ADTX (Aditxt)
Aditxt is an immune system company. It develops technologies (AditxtScore) for monitoring the immune system, as well as therapies for retraining it. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith in this sophisticated yet personalized R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ADTX-Aditxt&v=1772537054620 "A chart showing the difference between the consensus forecast and the actual stock price. ADTX (Aditxt)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Aditxt is an R&D biotech focused on "immune modulation"—retraining the immune system to treat autoimmune diseases and transplant rejection. This chart reflects analyst expectations across the immunopharmacology sector, demonstrating whether experts believe in this sophisticated R&D platform.
Analysts' consensus forecast for the overall market share price
Aditxt is a biotech company specializing in immune system monitoring and reprogramming technologies. This chart shows the overall market appetite for risk. For ADTX, an early-stage, high-risk company, overall market optimism (a rising chart) is critical for attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aditxt
Aditxt is an immune biotech company. They are developing immunotherapy (AditxtScore) to retrain the immune system (for autoimmune diseases) and diagnostics (for measuring immune status). This chart is a summary indicator of their dual (and highly speculative) R&D strategy. It reflects their (very slow) progress and their uphill battle for funding.
AKIMA Market Segment Index - Pharma immune
Aditxt specializes in the immune system, developing both diagnostic tests for immune monitoring and therapeutics. This approach to medicine is deeply personalized. This chart shows how their composite index compares to the sector average, reflecting how their innovations are ahead of the competition.
The AKIM Index for the overall market
Aditxt is a biotech company developing technologies for monitoring and modulating the immune system. It is actively acquiring other companies. This chart, which reflects the market average, provides a macro backdrop. It helps assess how ADTX, an aggressively growing microcap, compares to the overall macroeconomic situation.
